Kun Jiang

Title: Kun Jiang: Innovator in Chimeric Antigen Receptor Technology

Introduction

Kun Jiang is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapies for diseases associated with mesothelin expression. His work has the potential to impact cancer treatment and improve patient outcomes.

Latest Patents

Kun Jiang holds a patent for "Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof." This patent describes T cells engineered to express a chimeric antigen receptor (CAR), specifically an anti-mesothelin CAR. The invention also includes the use of these T cells in combination with a follicle-stimulating hormone receptor (FSHR) binding domain and/or a dominant negative transforming growth factor-β receptor II (dnTGFβRII). These advancements are aimed at treating diseases linked to mesothelin expression.

Career Highlights

Kun Jiang is associated with Nanjing Legend Biotech Co., Ltd., where he continues to push the boundaries of cancer research and therapy. His innovative approach to CAR technology has garnered attention in the scientific community and has the potential to lead to groundbreaking treatments.

Collaborations

Kun Jiang has collaborated with notable colleagues, including Qing Dai and Yuanyuan Peng. Their combined expertise enhances the research and development efforts at Nanjing Legend Biotech Co., Ltd.

Conclusion

Kun Jiang's contributions to the field of biotechnology, particularly through his patent on anti-mesothelin CAR constructs, highlight his role as an innovator in cancer treatment. His work exemplifies the potential of engineered T cells in advancing therapeutic options for patients.